Thomas Björk

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

José Baselga, Danny Rischin, Malcolm Ranson et al. · Journal of Clinical Oncology · 2002 · 829 citations

Serum Prostate Specific Antigen Complexed to<i>α</i>1-Antichymotrypsin as an Indicator of Prostate Cancer

Anders Christensson, Thomas Björk, Olle Nilsson et al. · The Journal of Urology · 1993 · 648 citations

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

Andrew J. Vickers, David Ulmert, Daniel D. Sjoberg et al. · BMJ · 2013 · 278 citations · Full text

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study

Andrew J. Vickers, A. Cronin, Thomas Björk et al. · BMJ · 2010 · 237 citations · Full text

Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years

Hans Lilja, David Ulmert, Thomas Björk et al. · Journal of Clinical Oncology · 2007 · 202 citations · Full text